hotspot -WSS

hotspot

author：fashion 2025-08-12 09:11:58 - browse：436

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

explore

WSS

Study finds gene variants tied to breast cancer risk in Black women

Cardiologists urge adding sexual orientation, gender identity to health records

A pediatrician calls for Congress to pass the child tax credit deal

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Liver decline slowed by off

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

hotspot

hotspot

explore

The high cost of giving birth even with insurance

UnitedHealth argues against case alleging wrongful AI care denials

Affirmative action in medical school literally saved lives

Dog Aging Project founders on what lies ahead after losing funding

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Dana Farber says 6 studies to be retracted and 31 corrected

Duchenne breakthrough therapy leaves behind pioneering families

TikTok, Instagram influencers need more rules for drug ads

Duchenne breakthrough therapy leaves behind pioneering families

Fentanyl is making it harder to start addiction treatment

hotspot

At flashy new research hub, AstraZeneca lays out ambitious growth goals

HPV vaccine, cervical cancer study delivers historic results

Dog Aging Project founders on what lies ahead after losing funding

Liver decline slowed by off

Cue Health, Covid

UnitedHealth argues against case alleging wrongful AI care denials

hotspot

explore

entertainment

hotspot